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TreatmentThe number of patients diagnosedwith heart failure (HF) is gradually increasing as a result of the increase in the
elderly population. As the proportion of patients admitted to the emergency room with the diagnosis of acute
heart failure increases, the opinion of cardiologists who are interested in heart failure has gained more impor-
tance in both the in-hospital management of these patients during the acute period and also in post-hospital
management. The current review aimed to help the clinicians determine the course of patients with HF, begin-
ning with the time of admission, according to the current guidelines and expert opinions.
© 2015 The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. All rights reserved. This is
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can develop as a result of worsening symptoms of existing heart failure
(HF) or de novo development of these symptoms. Patients with AHF
constitute a majority of the hospitalizations in cardiology clinics and
intensive care units (ICU). Thus, the strategy for the management of
these patients is critically important for both prognosis and for cost-
effectiveness.
The rate of hospitalizations due to AHFhas gradually increasedwith-
in recent years and patients aged above 65 constitute more than 80% of
these hospitalizations.1 In large scaled HF registries, female gender ac-
counts for 37–52% of the HF related hospitalizations, and while the fe-
male patient group is predominantly elderly, males remain relatively
younger.2–4 Several studies have demonstrated that 23–44% of the pa-
tients, who are admitted to the hospital with the diagnosis of AHF, are90 3462191268.
Cardiovascular Academy.
y. Production and hosting by Elsevdenovo AHF and approximately half of these have HF that are associated
with acute coronary syndrome (ACS).5,6 It has been demonstrated that
the in-hospital mortality of patients admitting with the diagnosis of
AHF varies between 4% and 7% in different studies and this ratio has in-
creased to 30–40% in patients admitted with cardiogenic shock (CS).4,7
In addition to in-hospital mortality, the duration of hospital stay and
the rate of readmission are also considerably high in patients with
AHF. The mean duration of hospital stay was nine days in the Euro
Heart Failure Survey.4 The rates of rehospitalization were 20% within
30 days and 50% within the following six months.8 Hence, in the ab-
sence of evidence, experienced based medicine is essential in many as-
pects of HF management.
How to tackle ﬁrst contact with the AHF patient?
Previous studies have particularly emphasized that the early man-
agement of patientswith AHF is important, as is the case in other cardio-
vascular emergencies.9,10 Upon ﬁrst contact with the patient with AHFier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
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should be immediately evaluated and monitored for vitals including
blood pressure, respiratory rate (RR), and noninvasive arterial oxygen
saturation (withpulse oximeter) (If saturation drops below95%, oxygen
therapy should be weighed and individualized according to the clinical
need. Patients with respiratory distress (RD) should be evaluated for
noninvasive ventilation.11 It has been demonstrated that transfer of
the patient to a center with a cardiology clinic/coronary intensive care
unit (CICU) and/or ICU in the shortest possible period has positive ef-
fects on the prognosis.12
How to determine in-hospital route of patients with HF?
The main goals in the treatment of AHF are to achieve improvement
in hemodynamic status and oxygenation initially, and ﬁnally, relief of
symptoms. In accordance with this purpose, the ﬁndings, obtained
from the initial evaluation of the patient are quite important in the de-
termination of the initial treatment strategy.11 Therefore, it is recom-
mended to tailor medical therapy by using nitrates and/or diuretics
according to the blood pressure and to the degree of congestion.13
Firstly, the degree of cardiac and pulmonary stabilization should be
assessed in patients with AHF. During this assessment, systolic and dia-
stolic blood pressure, heart rate (HR) and rhythm, body temperature,
and symptoms and signs of hypoperfusion, RR, the ability or inability
to lie in the supine position, effort dyspnea, the degree of hypoxia, and
the presence or absence of respiratory distress (RD) can provide infor-
mation related to cardiac and pulmonary stabilization. At the end of
these evaluations, unstable patients should be hospitalized in CICU or
ICU and further evaluations should be continued after the stabilization
of the vital signs of the patient.
After evaluating the degree of cardiopulmonary stabilization, the
ﬁndings related to congestion such as peripheral edema, audible rales,
and jugular venous pressure should also be evaluated and additional di-
agnostic tests should be performed thereafter.
Supporting elements for the determination of the route; diagnostic
tests
Electrocardiography is generally abnormal in patientswith AHFand it
is recommended to evaluate ECG in all patients with HF, as it could pro-
vide information related to the etiology of HF and the factors precipitat-
ing AHF.14 Furthermore, it is known thatwide QRS in patientswithHF is
associated with increased in-hospital mortality and increased mortality
during the follow-up period.15
Chest X-rays are among the routine tests in patients who are
suspected to have HF. It gives clues for cardiomegaly, pulmonary con-
gestion and for other reasons that could lead to dyspnea. Of note, a nor-
mal chest X-ray does not exclude AHF.16
Laboratory ﬁndings: routine tests including hemogram, blood glu-
cose, urea, creatinine, electrolytes, and liver enzymes should be per-
formed in all patients who are admitted to the hospital with the
suspicion of AHF. In addition to providing information related to the fac-
tors precipitating AHF, these parameters are also helpful in the selection
of the most appropriate treatment regime. In particular, creatinine and
electrolytes should be closely followed up in AHF patients. It has been
shown that renal functionworsens in 25% of the patients who are treat-
ed for AHF and thisworseningmight potentially be associatedwith poor
prognosis unless it is transient and mild.17 The liver function tests are
abnormal in 75% of the patients with AHF and this situation is most fre-
quently consistent with the severity and the clinical ﬁndings of AHF.18
As troponin levels can be above normal values in patients with AHF,
the diagnosis of ACS could not be excluded by only measuring troponin
levels; however, the high levels of troponin are important, as troponin is
a marker of poor prognosis in patients with HF.19 Blood gas analysis,
preferably venous, could be performed to evaluate the metabolic or re-
spiratory acidosis in patients with persistent RD who did not beneﬁtfrom initial therapy with oxygen or noninvasive ventilation.20 D-
Dimer test could be ordered in patients with suspected pulmonary em-
bolism. Furthermore, it is necessary to evaluate thyroid hormones in
AHF patients in order not to overlook hypo/hyperthyroidism.
Natriuretic peptides (NP): although atrial natriuretic peptides (ANP),
B-type natriuretic peptides (BNP), and C-type natriuretic peptides are
members of the natriuretic peptide family, BNP family is the most fre-
quently studied one. BNP is secreted as a response to ventricular wall
tension. Another form of BNP that is inactive and could be measured
in blood is NT-pro BNP. According to the current guidelines, during
the initial evaluation of AHF, BNP b 100 pg/ml, and NT-pro BNP
b300 pg/ml excludes the diagnosis of AHF.21 Although, there is no evi-
dence related to the beneﬁt of in-hospital monitorization of NP, it has
been demonstrated that 30–50% decrease in NT-pro BNP or an absolute
level below 350 pg/ml at the time of discharge is associated with good
prognosis.22
Emergency detailed echocardiographymight not be necessary during
the initial evaluation except in patients in CS. However, recent data sug-
gest that emergency bed-side focus echocardiography including basic
evaluation of heart and lungs might help triaging of these patients.
After stabilization of the patient, it is important to perform echocardiog-
raphy at any time during the hospitalization period, especially in
denovo AHF patients.
Site selection during the in-hospital journey: triaging for HF patient
AHF patients who are admitted to the ER, should ﬁrst be evaluated
according to whether they have shock criteria or not. If the patient is di-
agnosed with CS, cardiopulmonary stabilization should be immediately
achieved and then emergency echocardiography should be performed
to help determine the etiology of the shock. If there is clinical, electro-
cardiographic, and echocardiographic ﬁndings that support ACS, the pa-
tient should immediately be taken to the catheterization laboratory;
otherwise the patient should be hospitalized directly in the CICU or
ICU (Fig. 1).
CS is a clinical condition characterizedwith hypoperfusion (oliguria;
urine output b0.5 ml/kg/h for at least 6 h; impaired mental status;
livedo reticularis accompanied by cold extremities; blood lactate level
N2 mmol/l; metabolic acidosis; SvO2 b65%) and low SBP (b90 mmHg
for longer than 30 min in spite of sufﬁcient ﬂuid replacement).23 CS
might develop as a result of low cardiac output during end-stage of
chronic HF, and also it might develop in ST elevation myocardial infarc-
tion or in acute valvular pathologies.
Apart from the patientswithAHF and CS, patientswith severe symp-
toms and signs such as RR N25/min, SaO2 b90% or thosewith intubation,
SBP b90mmHg or hypoperfusion (confusion, oliguria, metabolic acido-
sis, cold extremities, mixed venous oxygen saturation b65%) should be
hospitalized in the CICU/ICU. Patients with AHF not having any of
these ﬁndings could be followed up in the ER or in the ward. Approxi-
mately 80% of AHF patients who are admitted to ER are hospitalized.24
It is thought that approximately 50% of the patients who are hospital-
ized after being admitted to the ER could be safely discharged after a
short period of follow-up.25 Presence of low risk criteria in AHF patients
such as normal oxygen saturation in room air, normal heart rate and
rhythm, absence of troponin elevation, absence of orthostatic hypoten-
sion, absence ofworsening renal and/or liver function, and normal urine
output alongwith a good response to treatment in the formof improved
dyspnea could help discharge patients rapidly from the ER.
Main factor that determines the duration of the in-hospital journey
of patients with HF: selection of an appropriate treatment strategy
Patients with low SBP and low cardiac output due to systolic dys-
function constitute only 5–10% of the patients who are hospitalized
due to AHF. The majority of them are patients with clinical ﬁndings
due to systemic and/or pulmonary congestion.
Acute Heart failure 
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Fig. 1. Time related algorithm for acute heart failure.
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ment protocol in AHF patients who have symptoms related to tissue
congestion caused by hypervolemia that is also named as “wet”. Inotro-
pic agents should be the ﬁrst choice in patients in whom hypotension
and tissue hypoperfusion-related symptoms are caused by low cardiac
output. When ﬁndings of both congestion and hypoperfusion are pres-
ent, the combined use of diuretics, vasodilators and inotropic agents in
a tailored manner gains importance.
The goal of diuretic therapy is to achieve euvolemia, thus dry weight,
with the minimum possible dose. During the administration of diuretic
therapy in HF, urine output of 40ml/h and daily weight loss of 1–1.5 kg
is usually targeted. Furosemide, which is the most frequently used di-
uretic in Turkey and around the world, could be initiated as a small in-
travenous dose that is equal to the routinely used oral dose or as an
intravenous high dose that is 2.5-folds of the routinely used oral dose.
In addition to the low dose and high dose protocols, the effects and ben-
eﬁts of bolus and infusion routes in patients with HF have been com-
pared in the DOSE (Diuretic Optimization Strategies Evaluation Trial)
study, and no signiﬁcant difference was detected between different
treatment strategies.26 In a meta-analysis of small-scaled studies com-
paring the infusion and bolus routes, no signiﬁcant difference was de-
tected between the two groups; however, it has been demonstrated
that diuresis is more effective by infusion.27,28 If sufﬁcient diuresis
could not be achieved in spite of a dose increase of the loop diuretic,
furosemide, a second diuretic agent could be added in the form of
consecutive nephron blockade. Although the thiazide group of diuretics
are commonly used, the evidence related to the use of high dose
spironolactone is increasing.29 Furthermore, a meta-analysis demon-
strated that improved weight loss, decreased duration of hospital stay,
and decreased rates of rehospitalization and mortality could be
achievedwith the combined use of furosemide andhypertonic saline in-
fusion in patientswith insufﬁcient diuresis throughdiuretic therapy and
in those who have extracellular ﬂuid accumulation.30 DAD HF II and
ROSE studies have demonstrated that diuretic therapy combined with
low dose dopamine infusion, which has been used as another alterna-
tive in patients with insufﬁcient diuresis, has no additional beneﬁt for
increasing diuresis and protecting renal functions.31,32 Another alterna-
tive for diuretic therapy in HF patients with hyponatremia is tolvaptan,
which is a vasopressin 2 receptor antagonist. The EVEREST study dem-
onstrated that tolvaptan has no effect on mortality and hospitalization;
however, it improves urine output and by increasing sodium, improves
congestive ﬁndings such as dyspnea and edema.33
Ultraﬁltration is also another treatment option to improve conges-
tive ﬁndings in hypervolemic patients. Ultraﬁltration that is added to
standard therapy has been compared to standard therapy alone in the
RAPID-CHF (relief for acutely ﬂuid-overloaded patients with decom-
pensated CHF) study and no signiﬁcant difference was detected be-
tween the two groups in terms of efﬁcacy and safety.34 The results of
studies on this subject are controversial.35,36 These data have beenevaluated in recent HF guidelines, and in the ESC 2012 HF guideline, ul-
traﬁltration was included among the controversial issues, as there is no
sufﬁcient evidence and a distinct recommendation has not been given.
However, the ACC/AHA guideline recommends a Class IIb drug for de-
creasing congestion in hypervolemic patients.
Vasodilators are also themain components of AHF treatment, as is di-
uretic therapy. It is thought that nitrovasodilator (nitroglycerine and ni-
troprusside) therapy has an important role in the improvement of
hemodynamic status in patients with AHF. There are data supporting
that the use of these agents is associated with lowmortality rates.10 Ni-
troglycerine treatment is started with 10–20 μg/min and can be in-
creased in a stepwise fashion up to 200 μg/min in AHF patients by
observing hemodynamic response. Nitroprusside can be initiated with
a dose of 0.3 μg/kg/min and increased up to 5 μg/kg/min under close he-
modynamicmonitorization. The duration of nitro-vasodilator therapy is
24–48 h. Beyond this time, tachyphylaxia or tolerance to nitroglycerin
or intoxication from nitroprusside may occur. It is recommended to
use IV nitrovasodilators by considering the abovementioned dose and
duration, to improve hemodynamic status by decreasing pulmonary
capillary wedge pressure (PCWP) and LV ﬁlling pressures in patients
with AHF who have SBP N110mmHg.37 Other agents for vasodilatation
are Serelaxin and Ularitide. These agents are currently being investigat-
ed in phase III clinical trials.
Although used less frequently than vasodilators and diuretics, positive
inotropic agents are also among the drugs thatmight be necessary to treat
AHF. These drugs aremostly used in patientswith low cardiac output and
hypotension due to systolic dysfunction or in patients with CS; this pa-
tient group constitutes 5–10% of the patients admitted with AHF. These
agents increase myocardial contractility and cardiac output and decrease
ventricular ﬁlling pressure and PCWP, and thus enable symptomatic and
hemodynamic stability.38 As they increase ischemic provocation and ar-
rhythmias, limited and short-termuse is recommended. The inotropic ef-
fects of dopamine start at doses of 3–5 μg/kg/min, and increase systemic
vascular resistance at higher doses. Its use in patients with severe hypo-
tension and/or CS is appropriate. Dobutamine is an inotropic agent that
is effective via B1 receptors which is preferred dopamine in patients
who have normal or close to normal blood pressure and low cardiac
output.39 It could be used at a dose range of 2–20 μg/kg/min and as the
dose increases, attention should be given to heart rate increase and ar-
rhythmias. Tolerance development 24–48 h after initial administration
and decreased effect in patients using beta blockers are its disadvantages.
Levosimendan leads to vasodilatation by opening ATP dependent potassi-
um channels in the vascular smooth muscles and thus decreases cardiac
preload and afterload, in addition to its inotropic effect by increasing
calcium-dependent myocardial contractile proteins.40 It has been dem-
onstrated that levosimendan enables hemodynamic improvement
when compared with dobutamine.41 Levosimendan is administered as
a 24-h IV infusion at a dose of 0.05–0.2 μg/kg/min following the adminis-
tration of a loading dose of 6–12 μg/kg/min in 10 min. Levosimendan is
34 H. Kaya, M.B. Yilmaz / International Journal of the Cardiovascular Academy 1 (2015) 31–35not recommended in cases with a systolic BP b85mmHg. It has been ob-
served that inotropic agents increase cardiac output more when they are
used together. A low dose dopamine and dobutamine combination is fre-
quently used in routine daily practice. Furthermore, a dobutamine and
levosimendan combination could also be preferred in resistant cases.42
Vasopressor agents are used to preserve organ perfusion in situations
where severe life-threateninghypotension develops and blood pressure
cannot be increased in spite of ﬂuid support and/or inotropic agents
such as CS. Epinephrine is generally used at a dose of 0.05–0.5 μg/kg/min.
It can be used in clinical practice if hypotension cannot be controlled.
Unless there is no serious hypotension, it is not recommended in de-
compensated HF. Epinephrine is not recommended as an inotropic
and vasopressor agent for CS. Norepinephrine is a strong vasoconstrictor
but a weak inotropic agent. In general, it is used to increase BP. It is gen-
erally used at doses of 0.2–1.0 μg/kg/min but it is not recommended for
decompensated HF.
Assist device therapy should be kept in mind for patients with AHF
who have no response to medical therapy, including inotropic therapy.
Intra-aortic balloon pump (IABP) is themost frequently used left ventri-
cle assist device (LVAD).43 However, in a recently performed IABP-
SHOCK II study, it has been demonstrated that IABP application in pa-
tients with acute myocardial infarction and CS, did not improve the
results.44 Furthermore, in a meta-analysis of seven randomized con-
trolled studies with IABP, it has been demonstrated that IABP caused
positive changes in hemodynamic parameters; however, it had no effect
on survival of the patients.45 In patients who had no response to stan-
dard therapy and IABP, other percutaneous LVADs (TandemHeart {Car-
diac Assist, Pittsburgh, PA, USA} and Impella LP 2.5 {Abiomed Europe
GmbH, Aachen, Germany}) are recommended.26,46 However, recent
data related to these devices are limited. However, short-termmechan-
ical support, including extracorporeal membrane oxygenation, could be
used in patientswith CSpatientswhohad no response tomaximalmed-
ical therapy.47Evidence-based in-hospital management of chronic oral therapy in
patients with HF
Oral treatment for HF should not be terminated in patients with AHF
as long as there is no hemodynamic instability (SBP b85 mmHg; heart
rate b50/min), hyperkalemia (potassium N5.5 mg/dl), or severe renal
dysfunction.37 In such situations, the daily oral dose could be decreased
or it could be discontinued until the patient is stabilized. In patients tak-
ing angiotensin converting enzyme inhibitor (ACEI) or angiotensin re-
ceptor blocker (ARB), if SBP is b85 mmHg, the treatment should be
discontinued. If SBP is between 85 mmHg and 100 mmHg, the dose
should be decreased or the treatment should be discontinued. Normo-
tensive or hypertensive patients could be reevaluated and the dose
could be increased. Furthermore, if creatinine is N2.5 mg/dl and esti-
mated glomerular ﬁltration rate (eGFR) is b30 ml/min/1.73 m2, the
treatment should be discontinued. In patients who are onmineralocor-
ticoid receptor antagonist (MRA) therapy, if SBP is b85 mmHg, creati-
nine is N2.5 mg/dl, or eGFR is b30 ml/min/1.73 m2 and/or potassium
is N5.5 mg/dl, treatment should be discontinued. If potassium is b3.5
mg/dl, increasing the dose of MRA could be an option. Related to the di-
uretic therapy regime, if SBP is b85 mmHg, diuretic therapy should be
discontinued; if SBP is between 85 mmHg and 100 mmHg, the dose
should be decreased. If potassium is N5.5 mg/dl when eGFR is N30
ml/min/1.73 m2 or if potassium is N5.5 mg/dl when creatinine is b2.5
mg/dl, reevaluation of the patient and increasing the diuretic dose
could be an option. The beta blocker therapy should be arranged
according to the blood pressure and HR of the patient. If HR and SBP are
appropriate, beta blockers could be safely continued in AHF except CS.48
If SBP is b85 mmHg and/or HR b50/min, beta blocker therapy should
be discontinued; if SBP is 85–100 mmHg and/or HR is 50–60/min,
decreasing the dose could be an option.When does the in-hospital journey of a patient with HF be stopped?
Which patients can be discharged?
Although it is attempted to limit the duration of hospital stay in all pa-
tients, discharge that is too earlymight cause repeated rehospitalizations.
It is necessary for patients with AHF to be discharged in stable, euvolemic
hemodynamic state, under optimal oral therapy for at least 24 h and
along with stable renal functions; otherwise discharge should be
delayed.11 Although the opinions related to NP measurement before dis-
charge is debated, the recommendation of the ACC/AHA guidelines as
clinical risk-prediction tools and/or biomarkers can be used to identify
patients at higher risk for post-discharge clinical events (Class IIa recom-
mendation Level of Evidence: B).21 Furthermore, patients with AHF
should be evaluated as a whole by considering comorbidities, psycholog-
ical and social factors, and the patient and the caregivers should be in-
formed in detail about HF. The information should include the etiology
of the disease; the drugs that the patient should use; diet; water and
salt consumption; other factors that could lead to decompensation of
HF; the symptoms and signs of HF; monitorization of weight, blood pres-
sure, and HR; and the exercises that the patient can perform.
In conclusion, the most important factor that would correctly guide
the patientwithHF in his/her difﬁcult in-hospital journey is the decision
of the physician in charge during follow-up. It is clear that continuing
the journey according to the route that has been developed by key opin-
ion leaders who are specialized in HF, in light of scientiﬁc and recent
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